Trial Profile
Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Expanded access; Therapeutic Use
- 05 Mar 2021 Status changed from recruiting to completed.
- 19 Mar 2020 The U.S. Food and Drug Administration media release,to date, the agency has already granted about 250 patients access to this product.
- 12 Mar 2020 New trial record